Literature DB >> 11922585

Autoimmune hepatitis and interferon beta-1a for multiple sclerosis.

Andrea Duchini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11922585     DOI： 10.1111/j.1572-0241.2002.05574.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  12 in total

1.  Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.

Authors:  V Christopher; N Scolding; R T Przemioslo
Journal:  J Neurol       Date:  2005-03-08       Impact factor: 4.849

2.  Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report.

Authors:  Atsushi Takahashi; Yukiko Kanno; Yuta Takahashi; Natsumi Sakamoto; Kyoko Monoe; Hironobu Saito; Kazumichi Abe; Junko Yokokawa; Atsushi Irisawa; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

3.  Autoimmune hepatitis induced by a single injection of interferon-β 1a in a patient with multiple sclerosis.

Authors:  Hiroki Yamaguchi; Kenji Sakai; Yoshinori Goto; Masahito Yamada
Journal:  J Neurol       Date:  2018-05-29       Impact factor: 4.849

Review 4.  Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Authors:  Helen Tremlett; Joel Oger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 5.  US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

Authors:  Steven L Galetta; Clyde Markowitz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.

Authors:  Peter Rieckmann; Paul O'Connor; Gordon S Francis; Graham Wetherill; Enrica Alteri
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 7.  Immunogenicity and other problems associated with the use of biopharmaceuticals.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Ther Adv Drug Saf       Date:  2011-06

8.  Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

Authors:  Gordon S Francis; Yves Grumser; Enrica Alteri; Alain Micaleff; Fanny O'Brien; Jonathan Alsop; Margaretha Stam Moraga; Neil Kaplowitz
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Authors:  Robert J Fontana; Paul Hayashi; Herbert L Bonkovsky; David E Kleiner; Sweta Kochhar; Jiezhun Gu; Marwan Ghabril
Journal:  Dig Dis Sci       Date:  2013-02-02       Impact factor: 3.487

Review 10.  Safety, Tolerability, and Immunogenicity of Interferons.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.